Targeted radionuclide therapy enhances prostate cancer response to immunotherapies

(Society of Nuclear Medicine and Molecular Imaging) Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate cancer that improves the effectiveness of immunotherapies. The research, presented at the Society of Nuclear Medicine and Molecular Imaging's 2020 Annual Meeting, shows that immunomodulation can be achieved with relatively low radiation dose that does not affect the normal immune system.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news